SCHEMBL5731315

SCHEMBL5731315

CCOC(=O)c1[nH]cc(-c2ccccn2)c1-c1ccc(F)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.44
KDM4E B2RXH2 2/20 0.44
CASP1 P29466 1/20 0.44
SQOR Q9Y6N5 1/20 0.43
POLB P06746 2/20 0.43
LMNA P02545 2/20 0.42
SLC11A2 P49281 2/20 0.42
KMT2A Q03164 4/20 0.42
ALDH1A1 P00352 3/20 0.42
MEN1 O00255 3/20 0.42
HPGD P15428 2/20 0.41
ALOX15 P16050 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
GAA P10253 1/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
MAPK14 Q16539 3/20 0.40
GCGR P47871 1/20 0.39
TP53 P04637 1/20 0.39
TGFBR1 P36897 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5730486 0.84 ALDH1A1 (0.53) HSD17B10KDM4EPOLBLMNAKMT2A
SCHEMBL5732191 0.84 PRKCZ (0.49) HSD17B10KDM4EPOLBLMNAKMT2A
SCHEMBL31189551 0.79 CYP2A6 (0.48) HSD17B10KDM4ECASP1POLBLMNA
SCHEMBL26112267 0.78 LMNA (0.48) HSD17B10KDM4ECASP1POLBLMNA
SCHEMBL6089942 0.78 ALDH1A1 (0.44) HSD17B10KDM4EPOLBLMNAKMT2A
SCHEMBL6092387 0.77 ALDH1A1 (0.46) HSD17B10KDM4EPOLBLMNAKMT2A
SCHEMBL15497074 0.77 POLB (0.46) KDM4EPOLBLMNAKMT2AALDH1A1
SCHEMBL31555586 0.77 L3MBTL1 (0.44) HSD17B10KDM4ECASP1LMNAKMT2A
SCHEMBL26111532 0.75 LMNA (0.50) HSD17B10KDM4ECASP1POLBLMNA
SCHEMBL5731692 0.75 ALDH1A1 (0.42) KDM4ESQORLMNASLC11A2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1691803-A1 N-ALKYL PYRROLES AS HMG-COA REDUCTASE INHIBITORS Warner-Lambert Company LLC (US) 2006-08-23 EP disclosed
US-20050154042-A1 N-alkyl pyrroles as HMG-CoA reductase inhibitors WARNER-LAMBERT COMPANY 2005-07-14 US disclosed
WO-2005056004-A1 N-ALKYL PYRROLES AS HMG-COA REDUCTASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2005-06-23 WO disclosed
US-6890934-B2 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-05-10 US disclosed
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-09-11 US disclosed
US-6573274-B1 Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-06-03 US disclosed
EP-1136492-A1 SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines PDE2A, PDE3A, PDE5A HSD17B10 2591/4885KDM4E 1599/4885CASP1 1435/4885
US-20050154042-A1 N-alkyl pyrroles as HMG-CoA reductase inhibitors HMGCR, DHCR7, CYP11A1 HSD17B10 26/4885KDM4E 1071/4885CASP1 3551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.